SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.

Sage Therapeutics shares gained 0.4% to trade at $9.11 on Tuesday. These analysts made changes to their price targets on Sage ...

Sage Therapeutics (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in ...

Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...

Eli Lilly has confirmed plans for a $1.3 billion takeover bid for Verve Therapeutics, upgrading a collaboration between the ...

The collaboration revenue from net sales of zurzuvae was $36.1 million for the full year 2024 and $13.8 million for the first ...

Recent health headlines spotlight Surgery Partners rejecting Bain Capital's offer, the U.S. betting on China's drug potential ...

As of June 17, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum ...

Verve Therapeutics stock nearly doubled Tuesday after Eli Lilly agreed to buy the gene-editing company for up to $1.3 billion ...